Post-infectious sequelae of travelers' diarrhea

Journal of Travel Medicine

Volumn 20, Issue 5, 2013, Pages 303-312

  Connor, Bradley A ^a   Riddle, Mark S ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B27 ANTIGEN; TOLL LIKE RECEPTOR 2;

ABDOMINAL DISCOMFORT; ACUTE MOTOR AXONAL NEUROPATHY; ANTIBIOTIC THERAPY; ARTHRALGIA; CAMPYLOBACTER; CAMPYLOBACTER JEJUNI; CAMPYLOBACTERIOSIS; CONJUNCTIVITIS; CONSTIPATION; CYTOMEGALOVIRUS; ENTEROBACTERIACEAE; EPISCLERITIS; EPSTEIN BARR VIRUS; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GENETIC RISK; GENETIC VARIABILITY; GUILLAIN BARRE SYNDROME; HLA SYSTEM; HUMAN; HYPOTENSION; INFECTION RISK; INFECTIOUS COMPLICATION; INTESTINE INFECTION; IRRITABLE COLON; MOLECULAR MIMICRY; MYCOPLASMA PNEUMONIAE; NONHUMAN; ORTHOSTATIC HYPERTENSION; PARESTHESIA; PSYCHOLOGICAL ASPECT; REACTIVE ARTHRITIS; REVIEW; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SHIGELLA; SYSTEMATIC REVIEW; TACHYCARDIA; TRAVELLER DIARRHEA; URINE RETENTION; UROGENITAL TRACT INFECTION; UVEITIS; YERSINIA INFECTION;

ARTHRITIS, REACTIVE; DIARRHEA; ENTEROBACTERIACEAE; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNE SYSTEM PROCESSES; INCIDENCE; IRRITABLE BOWEL SYNDROME; RISK FACTORS; TRAVEL; TRAVEL MEDICINE;

EID: 84883456874     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/jtm.12049     Document Type: Review

References (85)

1. Gascõn J,. Epidemiology, etiology and pathophysiology of traveler's diarrhea. Digestion 2006; 73 (Suppl 1): 102-108.
2. Connor BA,. Travelers' diarrhea. In: The yellow book. CDC health information for international travel 2012. New York: Oxford University Press, 2012: 56-60.
3. DuPont HL,. New insights and directions in travelers' diarrhea. Gastroenterol Clin North Am 2006; 35: 337-353 viii-ix.
4. DuPont HL, Ericsson CD, Farthing MJ, et al. Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med 2009; 16: 149-160.
5. Hill Gaston JS, Lillicrap MS,. Arthritis associated with enteric infection. Best Pract Res Clin Rheumatol 2003; 17: 219-239.
6. Lauhio A, Leirisalo-Repo M, Lahdevirta J, et al. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis. Arthritis Rheum 1991; 34: 6-14.
7. Swerdlow DL, Lee LA, Tauxe RV, et al. Reactive arthropathy following a multistate outbreak of Salmonella typhimurium infections. Program and abstracts of the 1990 Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology; 1990. [abstract 916].
8. Thomson GTD, DeRubeis DA, Hodge MA, Rajanayagam C,. Post-Salmonella reactive arthritis: late clinical sequelae in a point source cohort. Am J Med 1995; 98: 13-21.
9. Pope JE, Krizova A, Garg AX, et al. Campylobacter reactive arthritis: a systematic review. Semin Arthitis Rheum 2007; 37: 48-55.
10. Rohekar S, Tsui FW, Tsui HW, et al. Symptomatic acute reactive arthritis after an outbreak of Salmonella. J Rheumatol 2008; 35: 1599-1602.
11. Fendler C, Laitko S, Sorensen H, et al. Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis. Ann Rheum Dis 2001; 60: 337-343.
12. Connor BA, Johnson EJ, Soave R,. Reiter syndrome following protracted symptoms of Cyclospora infection. Emerg Infect Dis 2001; 7: 453-454.
13. Carlson DW, Finger DR,. Beaver Fever arthritis. J Clin Rheumatol 2004; 10: 86-88.
14. Birnbaum J, Bartlett JG, Gelber AC,. Clostridium difficile: an under-recognized cause of reactive arthritis? Clin Rheumatol 2008; 27: 253-255.
15. Yates JA, Stetz LC,. Reiter's syndrome (reactive arthritis) and travelers' diarrhea. J Travel Med 2006; 13: 54-56.
16. Curry JA, Riddle MS, Gormley RP, et al. The epidemiology of infectious gastroenteritis related reactive arthritis in U.S. military personnel: a case-control study. BMC Infect Dis 2010; 10: 266.
17. Schiellerup P, Krogfelt KA, Locht H,. A comparison of self-reported joint symptoms following infection with different enteric pathogens: effect of HLA-B27. J Rheumatol 2008; 35: 480-487.
18. Mattila L, Leirisalo-Repo M, Pelkonen P, et al. Reactive arthritis following an outbreak of Salmonella Bovismorbificans infection. J Infect 1998; 36: 289-295.
19. Thomson GT, Chiu B, De Rubeis D, et al. Immunoepidemiology of post-Salmonella reactive arthritis in a cohort of women. Clin Immunol Immunopathol 1992; 64: 227-232.
20. Inman RD, Johnston ME, Hodge M, et al. Postdysenteric reactive arthritis. A clinical and immunogenetic study following an outbreak of Salmonellosis. Arthritis Rheum 1988; 31: 1377-1383.
21. Tsui FW, Xi N, Rohekar S, et al. Toll-like receptor 2 variants are associated with acute reactive arthritis. Arthritis Rheum 2008; 58: 3436-3438.
22. Colmegna I, Cuchacovich R, Espinoza LR,. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clin Microbiol Rev 2004; 17: 348-369.
23. Granfors K, Merilahti-Palo R, Luukkainen R, et al. Persistence of Yersinia antigens in peripheral blood cells from patients with Yersinia enterocolitica O:3 infection with or without reactive arthritis. Arthritis Rheum 1998; 41: 855-862.
24. Kirveskari J, He Q, Holmstrom T, et al. Modulation of peripheral blood mononuclear cell activation status during Salmonella-triggered reactive arthritis. Arthritis Rheum 1999; 42: 2045-2054.
25. Kirveskari J, Jalkanen S, Maki-Ikola O, Granfors K,. Increased synovial endothelium binding and transendothelial migration of mononuclear cells during Salmonella infection. Arthritis Rheum 1998; 41: 1054-1063.
26. Hill Gaston JS, Cox C, Granfors K,. Clinical and experimental evidence for persistent Yersinia infection in reactive arthritis. Arthritis Rheum 1999; 42: 2239-2242.
27. Granfors K, Jalkanen S, Lindberg AA, et al. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet 1990; 335: 685-688.
28. Granfors K, Jalkanen S, Toivanen P, et al. Bacterial lipopolysaccharide in synovial fluid cells in Shigella triggered reactive arthritis. J Rheumatol 1992; 19: 500.
29. Granfors K, Jalkanen S, von Essen R, et al. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med 1989; 320: 216-221.
30. Nikkari S, Rantakokko K, Ekman P, et al. Salmonella-triggered reactive arthritis: use of polymerase chain reaction, immunocytochemical staining, and gas chromatography-mass spectrometry in the detection of bacterial components from synovial fluid. Arthritis Rheum 1999; 42: 84-89.
31. Siala M, Gdoura R, Fourati H, et al. Broad-range PCR, cloning and sequencing of the full 16S rRNA gene for detection of bacterial DNA in synovial fluid samples of Tunisian patients with reactive and undifferentiated arthritis. Arthritis Res Ther 2009; 11: R102.
32. Cox CJ, Kempsell KE, Gaston JS,. Investigation of infectious agents associated with arthritis by reverse transcription PCR of bacterial rRNA. Arthritis Res Ther 2003; 5: R1-R8.
33. Tsuchiya N, Husby G, Williams RC Jr, et al. Autoantibodies to the HLA-B27 sequence cross-react with the hypothetical peptide from the arthritis-associated Shigella plasmid. J Clin Invest 1990; 86: 1193-1203.
34. Lahesmaa R, Skurnik M, Vaara M, et al. Molecular mimickry between HLA B27 and Yersinia, Salmonella, Shigella and Klebsiella within the same region of HLA alpha 1-helix. Clin Exp Immunol 1991; 86: 399-404.
35. Stieglitz H, Fosmire S, Lipsky P,. Identification of a 2-Md plasmid from Shigella flexneri associated with reactive arthritis. Arthritis Rheum 1989; 32: 937-946.
36. Schwimmbeck PL, Yu DT, Oldstone MB,. Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med 1987; 166: 173-181.
37. Locht H, Krogfelt KA,. Comparison of rheumatological and gastrointestinal symptoms after infection with Campylobacter jejuni/coli and enterotoxigenic Escherichia coli. Ann Rheum Dis 2002; 61: 448-452.
38. Arnedo-Pena A, Beltrán-Fabregat J, Vila-Pastor B, et al. Reactive arthritis and other musculoskeletal sequelae following an outbreak of Salmonella hadar in Castellon, Spain. J Rheumatol 2010; 37: 1735-1742.
39. Yu RK, Usuki S, Ariga T,. Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases. Infect Immun 2006; 74: 6517-6527.
40. Winer JB,. Guillain-Barré syndrome. BMJ 2008; 337: a671.
41. Hughes RA, Cornblath DR,. Guillain-Barré syndrome. Lancet 2005; 366: 1653-1666.
42. Kuwabara S, Ogawara K, Koga M, et al. Hyperreflexia in Guillain-Barré syndrome: relation with acute motor axonal neuropathy and anti-GM1 antibody. J Neurol Neurosurg Psychiatry 1999; 67: 180-184.
43. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993; 33: 333-342.
44. Winer JB, Hughes RA, Osmond C,. A prospective study of acute idiopathic neuropathy. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry 1988; 51: 605-612.
45. Mori K, Hattori N, Sugiura M, et al. Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 2002; 58: 979-982.
46. Van Koningsveld R, Van Doorn PA, Schmitz PI, et al. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 2000; 54: 620-625.
47. Tam CC, Rodrigues LC, Petersen I, et al. Incidence of Guillain-Barré syndrome among patients with Campylobacter infection: a general practice research database study. J Infect Dis 2006; 194: 95-97.
48. Gilliss D, Cronquist A, Cartter M, et al. Vital signs: incidence and trends of infection with pathogens transmitted commonly through food-Foodborne Diseases Active Surveillance Network, 10 U.S. sites, 1996-2010. Morb Mortal Wkly Rep 2011; 60: 749-755.
49. Richardson RF Jr, Remler BF, Katirji B, Murad MH,. Guillain-Barré syndrome after Cyclospora infection. Muscle Nerve 1998; 21: 669-671.
50. Rhodes KM, Tattersfield AE,. Guillain-Barré syndrome associated with Campylobacter infection. BMJ 1982; 285: 173-174.
51. Allos BM,. Association between Campylobacter infection and Guillain-Barré syndrome. J Infect Dis 1997; 176: S125-S128.
52. Rees JH, Soudain SE, Gregson NA, Highes RA,. Campylobacter jejuni infection and Guillain Barré syndrome. N Engl J Med 1995; 333: 1374.
53. McCarthy N, Giesecke J,. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol 2001; 153: 610.
54. Koga M, Gilbert M, Takahashi M, et al. Comprehensive analysis of bacterial risk factors for the development of Guillain-Barré syndrome after Campylobacter jejuni enteritis. J Infect Dis 2006; 193: 547-555.
55. Hauck LJ, White C, Feasby TE, et al. Incidence of Guillain-Barré syndrome in Alberta, Canada: an administrative data study. J Neurol Neurosurg Psychiatry 2008; 79: 318-320.
56. Jiang GX, Cheng Q, Link H, de Pedro-Cuesta J,. Epidemiological features of Guillain-Barré syndrome in Sweden, 1978-93. J Neurol Neurosurg Psychiatry 1997; 62: 447-453.
57. Visser LH, Schmitz PI, Meulstee J, et al. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology 1999; 53: 598-604.
58. Winer JB, Hughes RA, Anderson MJ, et al. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry 1988; 51: 613-618.
59. Hadden RD, Karch H, Hartung HP, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology 2001; 56: 758-765.
60. Connor BA,. Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome. Clin Infect Dis 2005; 41 (Suppl 8): S577-S586.
61. Stewart GT,. Post-dysentericcolitis. BMJ 1950; 1: 405-409.
62. Spiller R,. Irritable bowel syndrome. Br Med Bull 2005; 72: 15-29.
63. Borgaonkar MR, Ford DC, Marshall JK, et al. The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection. Dig Dis Sci 2006; 51: 1026-1032.
64. McKendrick MW, Read NW,. Irritable bowel syndrome-post salmonella infection. J Infect 1994; 29: 1-3.
65. Spiller R, Garsed K,. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-1988.
66. Trivedi KH, Schlett CD, Tribble DR, et al. The impact of post-infectious functional gastrointestinal disorders and symptoms on the health-related quality of life of US military personnel returning from deployment to the Middle East. Dig Dis Sci 2011 Dec; 56: 3602-3609.
67. Stermer E, Lubezky A, Potasman I, et al. Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis 2006; 43: 898-901.
68. Okhuysen PC, Jiang ZD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99: 1774-1778.
69. Ilnyckyj A, Balachandra B, Elliott L, et al. Post-traveler's diarrhea irritable bowel syndrome: a prospective study. Am J Gastroenterol 2003; 98: 596-599.
70. Gwee KA, Collins SM, Read NW, et al. Increased rectal mucosal expression of interleukin 1ß in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 523-526.
71. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811.
72. Dunlop S, Jenkins D, Neal K, Spiller R,. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-1659.
73. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996; 347: 150-153.
74. Gwee K-A, Leong Y-L, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400-406.
75. Thabane M, Kottachchi DT, Marshall JK,. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535-544.
76. Parry SD, Barton JR, Welfare MR,. Factors associated with the development of post-infectious functional gastrointestinal diseases: does smoking play a role? Eur J Gastroenterol Hepatol 2005; 17: 1071-1075.
77. Neal KR, Barker L, Spiller RC,. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002; 51: 410-413.
78. van der Veek PPJ, van den Berg M, de Kroon YE, et al. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2510-2516.
79. Gonsalkorale WM, Perrey C, Pravica V, et al. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 91-93.
80. Thabane M, Marshall JK,. Post-infectious irritable bowel syndrome. World J Gastroenterol 2009; 15: 3591-3596.
81. Pimentel M, Chatterjee S, Chang C, et al. A new rat model links two contemporary theories in irritable bowel syndrome. Dig Dis Sci 2008; 53: 982-989.
82. Jee SR, Morales W, Low K, et al. ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. World J Gastroenterol 2010; 16: 3680-3686.
83. Wang LH, Fang XC, Pan GZ,. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096-1101.
84. Spiller RC,. Postinfectious irritable bowel syndrome. Gastroenterology 2003; 124: 1662-1671.
85. Spiller RC,. Role of infection in irritable bowel syndrome. J Gastroenterol 2007; 42 (Suppl 17): 41-47.